The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Novel Imaging for Genitourinary Cancers - Diagnostics and Theranostics

CME Available: https://auau.auanet.org/node/39411

Release Date: December, 2023

Expiration Date: December, 2024

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Review the latest clinical trials investigating the use of PET imaging agents in prostate, kidney, and urothelial cancer, including their diagnostic accuracy and impact on patient management.

2. Discuss the available PET imaging agents for prostate cancer, with a specific focus on PSMA (Prostate-Specific Membrane Antigen) PET imaging, including its mechanism of action and its potential for detection of primary tumors, lymph node metastases, and distant metastases.

3. Discuss the benefits of incorporating PET imaging, including PSMA PET, in guiding treatment decisions for GU cancers, such as its impact on treatment selection, treatment response assessment, and the potential for theranostic approaches.

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

Astellas and Pfizer, Inc

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 

Lantheus Medical Imaging

Merck & Co., Inc.